Wireframe preview

Best viewed on desktop.

This is a wireframe for review, not the finished site. The responsive (mobile) treatment comes in the design and build phase. Open this page on a screen at least 1200 px wide to see the layout as intended.

← The GRA Portfolio

Annate BiTherapeutics

Cancer treatment

Annate BiTherapeutics is developing a novel antibody capable of binding to cancer cells and killing them.

The particle, TLF (trypanosome lytic factor), is innately present in the human immune system, though at very low levels. Targeting multiple myeloma, a metastatic blood cancer, Annate’s technology can elevate levels of TLF in malignant cells to the point of cell death.

The average yearly cost for treating multiple myeloma can exceed $100,000. Annate’s treatment has the potential to reduce cost drastically less and while improving effectiveness.